Protagonist Therapeutics, Inc. (NASDAQ:PTGX) reported that Chief Financial Officer Ali Asif sold 1,750 shares of the company's common stock on April 20, 2026. The shares were disposed of at $105.47 apiece, producing gross proceeds of $184,572. According to the company disclosure, the sale was executed to cover tax withholding obligations arising from the settlement of restricted stock units.
After this disposition, Ali Asif's direct holding in Protagonist Therapeutics stands at 59,003 shares of common stock.
The share sale came as Protagonist's stock was trading near a 52-week high of $107.84, following a notable 130% gain over the prior twelve months. Market commentary referenced in the filing included an InvestingPro analysis that characterizes the stock as appearing overvalued at its current level. An additional InvestingPro Tip cited in the materials notes that analysts expect Protagonist to turn profitable this year despite recorded losses over the trailing twelve months. The filing also points investors toward PTGX’s Pro Research Report for more detailed analysis.
Separately, a series of analyst updates and company developments tied to Protagonist's lead asset, Icotyde, have been highlighted alongside the insider transaction. Jefferies has reiterated a Buy rating and maintained a $121 price target for Protagonist Therapeutics. Truist Securities also raised its price target to $121, citing commentary that pointed to rapid access and uptake for Icotyde in psoriasis treatment based on remarks from Johnson & Johnson’s earnings discussion.
Clear Street has been active in updating its valuation view on Protagonist. Following a management meeting after the American Academy of Dermatology Annual Meeting, Clear Street increased its price target to $116, describing Icotyde as a differentiated oral IL-23 treatment. Earlier actions from Clear Street had included a target raise to $104 subsequent to the FDA approval of Icotyde for moderate-to-severe psoriasis in eligible adults and adolescents.
The company also presented one-year Phase 3 data for Icotyde at the American Academy of Dermatology Annual Meeting, showcasing results that were cited in the analyst commentary and price-target revisions. Additionally, Johnson & Johnson’s first earnings report since Icotyde's launch was referenced as projecting strong expectations for the drug, including potential sales that could exceed $10 billion, a point that has informed bullish analyst sentiment.
Taken together, the insider sale, valuation commentary from InvestingPro, and a string of analyst price-target adjustments reflect active market attention on Protagonist Therapeutics and its lead therapy. The filing makes clear the sale was linked to tax obligations resulting from settled restricted stock units rather than other uses, and records the post-transaction shareholding for the CFO.